INAB

In8bio Inc

INAB, USA

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.

https://in8bio.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
INAB
stock
INAB

Latent View Analytics Ltd : Indian Analytics For Data Of World - Stock Correlation Metrics & Consistent Triple Returns Bollywood Helpline

Read more →
INAB
stock
INAB

CEO Change: What risks investors should watch in GLRE stock - Market Growth Review & Fast Exit/Entry Strategy Plans moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$46.9

Analyst Picks

Strong Buy

2

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.58

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-29.22 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-22.98 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.27

Low 1

High 0.3

Investors

* Institutions hold a combined 25.17% of the total shares of In8bio Inc

1.

BIOS CAPITAL MANAGEMENT, LP

(6.3146%)

since

2025/03/31

2.

Franklin Resources Inc

(4.1829%)

since

2025/06/30

3.

AIGH Capital Management, LLC

(3.3019%)

since

2025/06/30

4.

Franklin Biotechnology Discv A(acc)USD

(2.6477%)

since

2025/08/31

5.

Alyeska Investment Group, L.P.

(1.8169%)

since

2025/06/30

6.

Stonepine Capital Management Llc

(1.8158%)

since

2025/06/30

7.

Franklin Biotechnology Discovery A

(1.5347%)

since

2025/07/31

8.

Vanguard Group Inc

(1.3238%)

since

2025/06/30

9.

Vanguard Total Stock Mkt Idx Inv

(0.6844%)

since

2025/07/31

10.

Vanguard Institutional Extnd Mkt Idx Tr

(0.429%)

since

2025/07/31

11.

Geode Capital Management, LLC

(0.4146%)

since

2025/06/30

12.

Fidelity Extended Market Index

(0.2318%)

since

2025/07/31

13.

Northwestern Mutual Wealth Management Co

(0.0681%)

since

2025/06/30

14.

Fidelity Series Total Market Index

(0.0572%)

since

2025/07/31

15.

Spartan Extended Market Index Pool F

(0.0532%)

since

2025/07/31

16.

Northern Trust Extended Eq Market Idx

(0.0465%)

since

2025/06/30

17.

NT Ext Equity Mkt Idx Fd - L

(0.0465%)

since

2025/06/30

18.

Fidelity Total Market Index

(0.0449%)

since

2025/07/31

19.

Tower Research Capital LLC

(0.0334%)

since

2025/06/30

20.

Spartan Total Market Index Pool G

(0.0225%)

since

2025/07/31

21.

NT Ext Equity Mkt Idx Fd - NL

(0.0209%)

since

2025/06/30

22.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0162%)

since

2025/06/30

23.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0131%)

since

2025/06/30

24.

Fidelity Nasdaq Composite Index

(0.0125%)

since

2025/07/31

25.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0111%)

since

2024/12/31

26.

UBS Group AG

(0.0106%)

since

2025/06/30

27.

State St US Extended Mkt Indx NL Cl C

(0.0096%)

since

2025/08/31

28.

BlackRock Inc

(0.0019%)

since

2025/06/30

29.

Northern Trust Wilshire 5000

(0.0011%)

since

2025/06/30

30.

Bank of America Corp

(0.0005%)

since

2025/06/30

31.

Fidelity U.S. Equity Index Ins Trust

(0.0001%)

since

2025/07/31

32.

Goldman Sachs Group Inc

(0%)

since

2025/03/31

33.

683 Capital Management LLC

(0%)

since

2025/03/31

34.

State Street Corp

(0%)

since

2025/06/30

36.

Jane Street Group LLC

(0%)

since

2025/03/31

37.

Northern Trust Corp

(0%)

since

2025/06/30

38.

Sigma Planning Corp

(0%)

since

2025/06/30

39.

Citadel Advisors Llc

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.85

EPS Estimate

-0.05

EPS Difference

-0.8

Surprise Percent

-1600%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Possible Net-Net(5)
Quality
Low Quality Business(2.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.